persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2022-2-4-35-43persmed-67Research ArticleОБЗОРЫREVIEWERSМиокардиты, ассоциированные с иммунной противоопухолевой терапией Checkpoint-ингибиторамиImmune checkpoint inhibitor-induced myocarditisКушнареваЕ. А.KushnarevaE. A.

Кушнарева Екатерина Алексеевна, младший научный сотрудник НЦМУ «Центр персонализированной медицины»

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Kushnareva Ekaterina A., junior researcher, WorldClass Research Centre for Personalized Medicine

Akkuratova str., 2, Saint Petersburg, 197341

Kushnareva.cardio@gmail.comГаврилюкН. Д.GavrilyukN. D.

Гаврилюк Наталья Дмитриевна, кандидат медицинских наук, научный сотрудник НЦМУ «Центр персонализированной медицины»

Санкт-Петербург

Gavrilyuk Natalia D., PhD, researcher, World-Class Research Centre for Personalized Medicine

Saint Petersburg

ШугиноваТ. Н.ShuginovaT. N.

Шугинова Татьяна Николаевна, научный сотрудник НЦМУ «Центр персонализированной медицины», ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России, заведующий отделением функциональной диагностики и  общей терапии Санкт-Петербургского клинического научно-практического центра специализированных видов медицинской помощи (онкологический)

Санкт-Петербург, пос. Песочный

Shuginova Tatyana N., researcher, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Clinical Research and Practical Center for Specialized Oncological Care

Saint Petersburg

МоисееваО. М.MoiseevaO. M.

Моисеева Ольга Михайловна, доктор медицинских наук, директор Института сердца и сосудов, руководитель и главный научный сотрудник отдела некоронарогенных заболеваний сердца

Санкт-Петербург

Moiseeva Olga M., MD, Director of Heart and Vessels Institute, Chief Researcher of the noncoronary heart disease department

Saint Petersburg

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»РоссияAlmazov National Medical Research Centre, World-Class Research Centre for Personalized MedicineRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»; Государственное бюджетное учреждение здравоохранения «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»РоссияAlmazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine; Clinical Research and Practical Center for Specialized Oncological CareRussian Federation202216092022243543Copyright © Кушнарева Е.А., Гаврилюк Н.Д., Шугинова Т.Н., Моисеева О.М., 20222022Кушнарева Е.А., Гаврилюк Н.Д., Шугинова Т.Н., Моисеева О.М.Kushnareva E.A., Gavrilyuk N.D., Shuginova T.N., Moiseeva O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/67

Прогресс в консервативном лечении злокачественных новообразований сопряжен с появлением проблемы отдаленных последствий лекарственной терапии у пациентов с успешно пролеченной онкологией. Checkpoint-ингибиторы — группа противоопухолевых препаратов, относящаяся к иммунотерапии. Среди сердечно-сосудистых наиболее жизнеугрожающим осложнением являются Checkpoint-ассоциированные миокардиты. Данный обзор рассматривает вопросы механизмов развития осложнений иммунной терапии, эпидемиологии и особенностей течения Checkpoint-ассоциированных миокардитов.

Progress in conservative anticancer treatment is associated with an increase in long-term side effects of drugs in patients with successfully treated oncology. Immune checkpoint-inhibitors (ICI) belongs to group of anticancer immunotherapy. The most life threating cardiovascular adverse event are Checkpoint-associated myocarditis. This review provides information about potential mechanisms of immune related adverse events of ICI, epidemiology and clinical features of Checkpoint-associated myocarditis.

иммунотерапиякардиоонкологиякардиотоксичностьмиокардитCheckpoint-ингибиторыcardio-oncologycardiotoxicityImmune Checkpoint inhibitorsimmunotherapymyocarditisГрант Министерства науки и высшего образования Российской Федерации (соглашение No 075-15-2020-901)Grant from the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2020-901)ReferencesHargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol [Internet]. 2018;62(April):29–39. Available from: https://doi.org/10.1016/j.intimp.2018.06.001Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol [Internet]. 2018;62(April):29–39. Available from: https://doi.org/10.1016/j.intimp.2018.06.001Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol [Internet]. 2019;20(9):1239–51. Available from: http://dx.doi.org/10.1016/S1470-2045(19)30388-2Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol [Internet]. 2019;20(9):1239–51. Available from: http://dx.doi.org/10.1016/S1470-2045(19)30388-2Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Fiveyear outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33.Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Fiveyear outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33.Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/ metastatic melanoma therapy choice. Eur J Cancer [Internet]. 2021;149:222–32. Available from: https://doi.org/10.1016/j.ejca.2021.02.030Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/ metastatic melanoma therapy choice. Eur J Cancer [Internet]. 2021;149:222–32. Available from: https://doi.org/10.1016/j.ejca.2021.02.030Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, et al. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020;86(9):1778–89.Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, et al. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020;86(9):1778–89.Raschi E, Diemberger I, Poluzzi E, De Ponti F. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet [Internet]. 2018;392(10145):383. Available from: http://dx.doi.org/10.1016/S0140-6736(18)31549-6Raschi E, Diemberger I, Poluzzi E, De Ponti F. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet [Internet]. 2018;392(10145):383. Available from: http://dx.doi.org/10.1016/S0140-6736(18)31549-6Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–55.Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–55.Cho J, Kim HS, Ku BM, Choi Y La, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2019;37(24):2162–70.Cho J, Kim HS, Ku BM, Choi Y La, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2019;37(24):2162–70.Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open [Internet]. 2021;6(5):100252. Available from: https://doi.org/10.1016/j.esmoop.2021.100252Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open [Internet]. 2021;6(5):100252. Available from: https://doi.org/10.1016/j.esmoop.2021.100252Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science (80- ). 2011;331(6024):1565–70.Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science (80- ). 2011;331(6024):1565–70.Radoja S, Rao TD, Hillman D, Frey AB. Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo. J Immunol. 2000;164(5):2619–28.Radoja S, Rao TD, Hillman D, Frey AB. Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo. J Immunol. 2000;164(5):2619–28.Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood. 2018;131(1):58–67.Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood. 2018;131(1):58–67.Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (80- ). 1996;271(5256):1734–6.Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (80- ). 1996;271(5256):1734–6.Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–22.Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–22.Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–6.Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–6.Sosman JA, Haanen JB, Gonzalez R, Robert C, Ph D, Schadendorf D, et al. New england journal. 2010;711–23.Sosman JA, Haanen JB, Gonzalez R, Robert C, Ph D, Schadendorf D, et al. New england journal. 2010;711–23.Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1-deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563–72.Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1-deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563–72.Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity. 1999;11(2):141– 51.Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity. 1999;11(2):141– 51.Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (80- ). 2001;291(5502):319–22.Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (80- ). 2001;291(5502):319–22.Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci [Internet]. 2015;36(9):587–95. Available from: http://dx.doi.org/10.1016/j.tips.2015.06.005Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci [Internet]. 2015;36(9):587–95. Available from: http://dx.doi.org/10.1016/j.tips.2015.06.005Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–67.Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–67.Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):1–11.Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):1–11.Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, et al. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects with Outcomes in Patients with Advanced Melanoma. JAMA Oncol. 2019;5(6):906–8.Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, et al. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects with Outcomes in Patients with Advanced Melanoma. JAMA Oncol. 2019;5(6):906–8.Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Association between Immune-Related Adverse Events and RecurrenceFree Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2020;6(4):519–27.Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Association between Immune-Related Adverse Events and RecurrenceFree Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2020;6(4):519–27.Flatz L, Berner F, Bomze D, Diem S, Ali OH, Fässler M, et al. Association of Checkpoint InhibitorInduced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1043–7.Flatz L, Berner F, Bomze D, Diem S, Ali OH, Fässler M, et al. Association of Checkpoint InhibitorInduced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1043–7.Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockadeinduced colitis. Nat Commun [Internet]. 2016;7:1–8. Available from: http://dx.doi.org/10.1038/ncomms10391Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockadeinduced colitis. Nat Commun [Internet]. 2016;7:1–8. Available from: http://dx.doi.org/10.1038/ncomms10391Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. Gut microbiota signatures are associated with toxicity to combined CTLA4 and PD-1 blockade. Nat Med. 2021;27(8):1432–41.Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, et al. Gut microbiota signatures are associated with toxicity to combined CTLA4 and PD-1 blockade. Nat Med. 2021;27(8):1432–41.Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever M, Wescott EC, et al. HHS Public Access. 2021;11(3):614–25.Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever M, Wescott EC, et al. HHS Public Access. 2021;11(3):614–25.Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of Programmed death-1 and its ligand in cardiac injury models: Interaction with GADD153. PLoS One. 2015;10(4):1–17.Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of Programmed death-1 and its ligand in cardiac injury models: Interaction with GADD153. PLoS One. 2015;10(4):1–17.Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure. Front Cardiovasc Med. 2022;8(January):1–8.Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure. Front Cardiovasc Med. 2022;8(January):1–8.Salem JE, Manouchehri A, Moey M, LebrunVignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89.Salem JE, Manouchehri A, Moey M, LebrunVignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89.Кушнарева Е.А., Моисеева О.М. Миокардиты, ассоциированные с терапией ингибиторами контрольных точек: систематический анализ клинических случаев. Российский кардиологический журнал. 2020;25(11):3910.Kushnareva EA, Moiseeva OM. Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology. 2020;25(11):3910. In RussianPuzanov I, Subramanian P, Yatsynovich YV., Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6):1–11.Puzanov I, Subramanian P, Yatsynovich YV., Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6):1–11.

The authors declare that there are no conflicts of interest present.